Antidepressants and driver impairment: Empirical evidence from a standard on-the-road test

Journal of Clinical Psychiatry

Volumn 64, Issue 1, 2003, Pages 20-29

  Ramaekers, Johannes G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BROFAROMINE; BROMAZEPAM; DOSULEPIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; LEVOPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORDAZEPAM; OXAPROTILINE; PAROXETINE; PLACEBO; VENLAFAXINE;

ADULT; AGED; ALCOHOL BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG EFFECT; EMPIRICISM; EVIDENCE BASED MEDICINE; HAZARD; HUMAN; HUMAN EXPERIMENT; LETHARGY; LINEAR REGRESSION ANALYSIS; MEASUREMENT; MULTICENTER STUDY; NIGHT; NORMAL HUMAN; POSITION; PREDICTION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SELF CONCEPT; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STANDARD; STANDARD DEVIATION OF LATERAL POSITION; TRAFFIC; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037269674     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0106     Document Type: Article

References (34)

1. Ramaekers JG. Behavioural toxicity of medicinal drugs: practical consequences, incidence, management and avoidance. Drug Saf 1998;18:189-208
2. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992;136:873-883
3. Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994;5:591-598
4. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331-1336
5. Guidelines on psychotropic drugs for the EC: clinical investigation of medicinal products in the treatment of generalized anxiety disorder, panic disorder and obsessive-compulsive disorder. Eur Neuropsychopharmacol 1995:5:151-155
6. O'Hanlon JF, Haak TW, Blaauw GJ, et al. Diazepam impairs lateral position control in highway driving. Science 1982;217:79-81
7. O'Hanlon JF, Brookhuis K, Louwerens J, et al. Performance testing as part of drug registration. In: Drugs and Driving. O'Hanlon JF. de Grier JJ, eds. London, England: Taylor & Francis; 1986:311-327
8. Louwerens JW, Gloerich ABM, De Vries G, et al. The relationship between drivers' blood alcohol concentration and actual driving performance during high speed travel. In: Alcohol, Drugs and Traffic Safety-T86. Noordzij P. ed. Amsterdam, the Netherlands: Elsevier; 1987:183-186
9. Borkenstein RF, Crowther RF, Schumate RP, et al. The Role of the Drinking Driver in Traffic Accidents. Bloomington, Ind: University of Indiana, Dept of Police Administration; 1964
10. Louwerens JW, Brookhuis KA, O'Hanlon JF. The Effects of the Antidepressants Oxaprotiline, Mianserin, Amitriptyline and Doxepin upon Actual Driving Performance. Groningen, the Netherlands: Traffic Research Centre; 1984
11. Schoenmakers EAJM, Robbe HWJ, O'Hanlon JF, Acute and Subchronic Effects of the Antidepressants Levoprotiline and Doxepin on the Performance of Healthy Volunteers in Psychometric and Actual Driving Tests. Maastricht, the Netherlands: University of Maastricht, Institute for Human Psychopharmacology; 1989
12. Ramaekers JG, van Veggel LM, O'Hanlon JF. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep. Clin Neuropharmacol 1994;17(suppl 1):S9-S18
13. Robbe HW, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995;5:35-42
14. van Laar MW, van Willigenburg AP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995;15:30-40
15. Ramaekers JG, Swijgman HF, O'Hanlon JF. Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology (Berl) 1992;106(suppl):S62-S67
16. O'Hanlon JF, Robbe HW, Vermeeren A, et al. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998;18:212-221
17. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995;39:397-404
18. Ramaekers JG, Muntjewerff D, Van Veggel LMA, et al. Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Hum Psychopharmacol Clin Exp 1998;13(suppl 2):S87-S97
19. Ramaekers JG, Ansseau M, Muntjewerff ND, et al. Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. Int Clin Psychopharmacol 1997;12:159-169
20. Bremner JD. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J Clin Psychiatry 1995;56:519-525
21. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285
22. Beasley CM, Sayler ME, Weis AM, et al. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 1992;12:328-333
23. Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 1996;57(suppl 2):39-44
24. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 1997; 58:393-398
25. Ferguson JM, Mendels J, Manowitz NR. Dothiepin versus doxepin in major depression: results of a multicenter, placebo-controlled trial. J Clin Psychiatry 1994;55:258-263
26. Wilcox CS, Cohn JB, Katz BB, et al. A double-blind, placebo controlled study comparing mianserin and amitriptyline in moderately depressed outpatients. Int Clin Psychopharmacol 1994;9:271-279
27. Claghorn JL, Earl CQ, Walczak DD, et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 1996;16:113-120
28. Claghorn JL, Kiev A, Rickels K, et al. Paroxetine versus placebo: double-blind comparison in depressed patients. J Clin Psychiatry 1992;53:434-438
29. Tiller JW, Johnson GF, Burrows GD. Moclobemide for depression: an Australian psychiatric practice study. J Clin Psychopharmacol 1995;15(suppl 2):31-34
30. DeVane CL. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999;19:443-466
31. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57
32. Rotzinger S, Bourin M, Akimoto Y, et al. Metabolism of some "second"and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 1999;19:427-442
33. Fullerton T, Gengo FM. Central nervous system effects of drug therapy in aged individuals. In: Streufert S, Gengo FM, eds. Effects of Drugs on Human Functioning. Basel, Switzerland: Karger; 1993:134-168
34. Sanders AF. Drugs, driving and the measurement of human performance. In: Drugs and Driving. O'Hanlon JF, de Grier JJ, eds. London, England: Taylor & Francis; 1986:3-16